NCT04404283 2026-03-17
ECHELON-3
Seagen Inc.
Phase 3 Active not recruiting
Clinical Trials
13 trialsNCT04628494 2026-03-03
EPCORE DLBCL-1
Genmab
Phase 3 Active not recruiting
NCT07226752 2026-03-03
A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China
Genmab
Phase 3 Active not recruiting
NCT03274492 2026-02-06
POLARIX
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT06091865 2026-02-05
OLYMPIA-3
Regeneron Pharmaceuticals
Phase 3 Active not recruiting
NCT04384484 2026-01-26
LOTIS 5
ADC Therapeutics S.A.
Phase 3 Active not recruiting
NCT04408638 2026-01-07
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT03570892 2026-01-06
BELINDA
Novartis
Phase 3 Active not recruiting
NCT05429268 2025-12-10
firmMIND
Incyte Corporation
Phase 3 Active not recruiting
NCT04824092 2025-09-08
frontMIND
Incyte Corporation
Phase 3 Active not recruiting
NCT05578976 2025-01-23
EPCORE DLBCL-2
Genmab
Phase 3 Active not recruiting
NCT04231448 2024-12-05
DEB
Chipscreen Biosciences, Ltd.
Phase 3 Active not recruiting
NCT03213977 2024-03-27
R-DA-EDOCH Versus R-CEOP90, With/Without Upfront Auto-HSCT in Young Patients With High-risk DLBCL
Fujian Medical University
Phase 3 Active not recruiting